Industry Research Reports

Home > Reports > Pharma & Healthcare > Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published Date: 2024-01-11

Pages: 101 Pages

Report ld: 2622325

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Pegfilgrastim Biosimilar Market Size(US$)

CAGR 2024-2030

6.8%

Market Size,2030

USD 2,407

Million

Market Snapshot

Market Size in 2024 (Value)

US$ 1,622 million

Market Forecast in 2030(Value)

US$ 2,407 million

CAGR

6.8%

Years Considered

2019-2030

Base Year

2024

Forecast Period

2024-2030

Source: Secondary research, interviews with experts, and QYResearch analysis

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1522 million in 2023 and is forecast to a readjusted size of US$ 2407 million by 2030 with a CAGR of 6.8% during the forecast period 2024-2030

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

MARKET SEGMENTATION

By Company

Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Chemotherapy Treatment
Transplantation

Segment by Application

Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Pegfilgrastim Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Pegfilgrastim Biosimilar by region & country, by Type, and by Application.

The Pegfilgrastim Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pegfilgrastim Biosimilar.

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Pegfilgrastim Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Pegfilgrastim Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Pegfilgrastim Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Pegfilgrastim Biosimilar Product Introduction

1.2 Global Pegfilgrastim Biosimilar Market Size Forecast

1.2.1 Global Pegfilgrastim Biosimilar Sales Value (2019-2030)

1.2.2 Global Pegfilgrastim Biosimilar Sales Volume (2019-2030)

1.2.3 Global Pegfilgrastim Biosimilar Sales Price (2019-2030)

1.3 Pegfilgrastim Biosimilar Market Trends & Drivers

1.3.1 Pegfilgrastim Biosimilar Industry Trends

1.3.2 Pegfilgrastim Biosimilar Market Drivers & Opportunity

1.3.3 Pegfilgrastim Biosimilar Market Challenges

1.3.4 Pegfilgrastim Biosimilar Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Pegfilgrastim Biosimilar Players Revenue Ranking (2023)

2.2 Global Pegfilgrastim Biosimilar Revenue by Company (2019-2024)

2.3 Global Pegfilgrastim Biosimilar Players Sales Volume Ranking (2023)

2.4 Global Pegfilgrastim Biosimilar Sales Volume by Company Players (2019-2024)

2.5 Global Pegfilgrastim Biosimilar Average Price by Company (2019-2024)

2.6 Key Manufacturers Pegfilgrastim Biosimilar Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Pegfilgrastim Biosimilar Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Pegfilgrastim Biosimilar

2.9 Pegfilgrastim Biosimilar Market Competitive Analysis

2.9.1 Pegfilgrastim Biosimilar Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Pegfilgrastim Biosimilar Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pegfilgrastim Biosimilar as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Chemotherapy Treatment

3.1.2 Transplantation

3.2 Global Pegfilgrastim Biosimilar Sales Value by Type

3.2.1 Global Pegfilgrastim Biosimilar Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Pegfilgrastim Biosimilar Sales Value, by Type (2019-2030)

3.2.3 Global Pegfilgrastim Biosimilar Sales Value, by Type (%) (2019-2030)

3.3 Global Pegfilgrastim Biosimilar Sales Volume by Type

3.3.1 Global Pegfilgrastim Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Pegfilgrastim Biosimilar Sales Volume, by Type (2019-2030)

3.3.3 Global Pegfilgrastim Biosimilar Sales Volume, by Type (%) (2019-2030)

3.4 Global Pegfilgrastim Biosimilar Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacies

4.1.2 Mail-Order Pharmacies

4.1.3 Retail Pharmacies

4.2 Global Pegfilgrastim Biosimilar Sales Value by Application

4.2.1 Global Pegfilgrastim Biosimilar Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Pegfilgrastim Biosimilar Sales Value, by Application (2019-2030)

4.2.3 Global Pegfilgrastim Biosimilar Sales Value, by Application (%) (2019-2030)

4.3 Global Pegfilgrastim Biosimilar Sales Volume by Application

4.3.1 Global Pegfilgrastim Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Pegfilgrastim Biosimilar Sales Volume, by Application (2019-2030)

4.3.3 Global Pegfilgrastim Biosimilar Sales Volume, by Application (%) (2019-2030)

4.4 Global Pegfilgrastim Biosimilar Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Pegfilgrastim Biosimilar Sales Value by Region

5.1.1 Global Pegfilgrastim Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Pegfilgrastim Biosimilar Sales Value by Region (2019-2024)

5.1.3 Global Pegfilgrastim Biosimilar Sales Value by Region (2025-2030)

5.1.4 Global Pegfilgrastim Biosimilar Sales Value by Region (%), (2019-2030)

5.2 Global Pegfilgrastim Biosimilar Sales Volume by Region

5.2.1 Global Pegfilgrastim Biosimilar Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Pegfilgrastim Biosimilar Sales Volume by Region (2019-2024)

5.2.3 Global Pegfilgrastim Biosimilar Sales Volume by Region (2025-2030)

5.2.4 Global Pegfilgrastim Biosimilar Sales Volume by Region (%), (2019-2030)

5.3 Global Pegfilgrastim Biosimilar Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Pegfilgrastim Biosimilar Sales Value, 2019-2030

5.4.2 North America Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Pegfilgrastim Biosimilar Sales Value, 2019-2030

5.5.2 Europe Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Pegfilgrastim Biosimilar Sales Value, 2019-2030

5.6.2 Asia Pacific Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Pegfilgrastim Biosimilar Sales Value, 2019-2030

5.7.2 South America Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Pegfilgrastim Biosimilar Sales Value, 2019-2030

5.8.2 Middle East & Africa Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Pegfilgrastim Biosimilar Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Pegfilgrastim Biosimilar Sales Value

6.2.1 Key Countries/Regions Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.2.2 Key Countries/Regions Pegfilgrastim Biosimilar Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.3.2 United States Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Pegfilgrastim Biosimilar Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.4.2 Europe Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Pegfilgrastim Biosimilar Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.5.2 China Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

6.5.3 China Pegfilgrastim Biosimilar Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.6.2 Japan Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Pegfilgrastim Biosimilar Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.7.2 South Korea Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Pegfilgrastim Biosimilar Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.8.2 Southeast Asia Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Pegfilgrastim Biosimilar Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Pegfilgrastim Biosimilar Sales Value, 2019-2030

6.9.2 India Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

6.9.3 India Pegfilgrastim Biosimilar Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Novartis

7.1.1 Novartis Company Information

7.1.2 Novartis Introduction and Business Overview

7.1.3 Novartis Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Novartis Pegfilgrastim Biosimilar Product Offerings

7.1.5 Novartis Recent Development

7.2 Mylan

7.2.1 Mylan Company Information

7.2.2 Mylan Introduction and Business Overview

7.2.3 Mylan Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Mylan Pegfilgrastim Biosimilar Product Offerings

7.2.5 Mylan Recent Development

7.3 Coherus BioSciences

7.3.1 Coherus BioSciences Company Information

7.3.2 Coherus BioSciences Introduction and Business Overview

7.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Coherus BioSciences Pegfilgrastim Biosimilar Product Offerings

7.3.5 Coherus BioSciences Recent Development

7.4 Mundipharma International

7.4.1 Mundipharma International Company Information

7.4.2 Mundipharma International Introduction and Business Overview

7.4.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Mundipharma International Pegfilgrastim Biosimilar Product Offerings

7.4.5 Mundipharma International Recent Development

7.5 Biocon

7.5.1 Biocon Company Information

7.5.2 Biocon Introduction and Business Overview

7.5.3 Biocon Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Biocon Pegfilgrastim Biosimilar Product Offerings

7.5.5 Biocon Recent Development

7.6 Intas Pharmaceuticals

7.6.1 Intas Pharmaceuticals Company Information

7.6.2 Intas Pharmaceuticals Introduction and Business Overview

7.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Offerings

7.6.5 Intas Pharmaceuticals Recent Development

7.7 Pfizer

7.7.1 Pfizer Company Information

7.7.2 Pfizer Introduction and Business Overview

7.7.3 Pfizer Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Pfizer Pegfilgrastim Biosimilar Product Offerings

7.7.5 Pfizer Recent Development

7.8 Dr Reddy’s Laboratories

7.8.1 Dr Reddy’s Laboratories Company Information

7.8.2 Dr Reddy’s Laboratories Introduction and Business Overview

7.8.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Offerings

7.8.5 Dr Reddy’s Laboratories Recent Development

8 Industry Chain Analysis

8.1 Pegfilgrastim Biosimilar Industrial Chain

8.2 Pegfilgrastim Biosimilar Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Pegfilgrastim Biosimilar Sales Model

8.5.2 Sales Channel

8.5.3 Pegfilgrastim Biosimilar Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Pegfilgrastim Biosimilar Market Trends

Table 2. Pegfilgrastim Biosimilar Market Drivers & Opportunity

Table 3. Pegfilgrastim Biosimilar Market Challenges

Table 4. Pegfilgrastim Biosimilar Market Restraints

Table 5. Global Pegfilgrastim Biosimilar Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Pegfilgrastim Biosimilar Revenue Market Share by Company (2019-2024)

Table 7. Global Pegfilgrastim Biosimilar Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Pegfilgrastim Biosimilar Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Pegfilgrastim Biosimilar Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Pegfilgrastim Biosimilar Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Pegfilgrastim Biosimilar Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Pegfilgrastim Biosimilar

Table 13. Global Pegfilgrastim Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pegfilgrastim Biosimilar as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Pegfilgrastim Biosimilar Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Pegfilgrastim Biosimilar Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Pegfilgrastim Biosimilar Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Pegfilgrastim Biosimilar Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Pegfilgrastim Biosimilar Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Pegfilgrastim Biosimilar Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Pegfilgrastim Biosimilar Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Pegfilgrastim Biosimilar Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Pegfilgrastim Biosimilar Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Pegfilgrastim Biosimilar Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Pegfilgrastim Biosimilar Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Pegfilgrastim Biosimilar Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Pegfilgrastim Biosimilar Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Pegfilgrastim Biosimilar Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Pegfilgrastim Biosimilar Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Pegfilgrastim Biosimilar Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Pegfilgrastim Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Pegfilgrastim Biosimilar Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Pegfilgrastim Biosimilar Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Pegfilgrastim Biosimilar Sales Value by Region (2019-2024) & (%)

Table 44. Global Pegfilgrastim Biosimilar Sales Value by Region (2025-2030) & (%)

Table 45. Global Pegfilgrastim Biosimilar Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Pegfilgrastim Biosimilar Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Pegfilgrastim Biosimilar Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Pegfilgrastim Biosimilar Sales Volume by Region (2019-2024) & (%)

Table 49. Global Pegfilgrastim Biosimilar Sales Volume by Region (2025-2030) & (%)

Table 50. Global Pegfilgrastim Biosimilar Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Pegfilgrastim Biosimilar Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Pegfilgrastim Biosimilar Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Pegfilgrastim Biosimilar Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Pegfilgrastim Biosimilar Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Pegfilgrastim Biosimilar Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Pegfilgrastim Biosimilar Sales Volume, (2025-2030) & (K Units)

Table 57. Novartis Company Information

Table 58. Novartis Introduction and Business Overview

Table 59. Novartis Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Novartis Pegfilgrastim Biosimilar Product Offerings

Table 61. Novartis Recent Development

Table 62. Mylan Company Information

Table 63. Mylan Introduction and Business Overview

Table 64. Mylan Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. Mylan Pegfilgrastim Biosimilar Product Offerings

Table 66. Mylan Recent Development

Table 67. Coherus BioSciences Company Information

Table 68. Coherus BioSciences Introduction and Business Overview

Table 69. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Coherus BioSciences Pegfilgrastim Biosimilar Product Offerings

Table 71. Coherus BioSciences Recent Development

Table 72. Mundipharma International Company Information

Table 73. Mundipharma International Introduction and Business Overview

Table 74. Mundipharma International Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Mundipharma International Pegfilgrastim Biosimilar Product Offerings

Table 76. Mundipharma International Recent Development

Table 77. Biocon Company Information

Table 78. Biocon Introduction and Business Overview

Table 79. Biocon Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Biocon Pegfilgrastim Biosimilar Product Offerings

Table 81. Biocon Recent Development

Table 82. Intas Pharmaceuticals Company Information

Table 83. Intas Pharmaceuticals Introduction and Business Overview

Table 84. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Offerings

Table 86. Intas Pharmaceuticals Recent Development

Table 87. Pfizer Company Information

Table 88. Pfizer Introduction and Business Overview

Table 89. Pfizer Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Pfizer Pegfilgrastim Biosimilar Product Offerings

Table 91. Pfizer Recent Development

Table 92. Dr Reddy’s Laboratories Company Information

Table 93. Dr Reddy’s Laboratories Introduction and Business Overview

Table 94. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Offerings

Table 96. Dr Reddy’s Laboratories Recent Development

Table 97. Key Raw Materials Lists

Table 98. Raw Materials Key Suppliers Lists

Table 99. Pegfilgrastim Biosimilar Downstream Customers

Table 100. Pegfilgrastim Biosimilar Distributors List

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

List of Figures

Figure 1. Pegfilgrastim Biosimilar Product Picture

Figure 2. Global Pegfilgrastim Biosimilar Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Pegfilgrastim Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Pegfilgrastim Biosimilar Sales Volume (2019-2030) & (K Units)

Figure 5. Global Pegfilgrastim Biosimilar Sales Price (2019-2030) & (US$/Unit)

Figure 6. Pegfilgrastim Biosimilar Report Years Considered

Figure 7. Global Pegfilgrastim Biosimilar Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Pegfilgrastim Biosimilar Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Pegfilgrastim Biosimilar Revenue in 2023

Figure 10. Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Chemotherapy Treatment Picture

Figure 12. Transplantation Picture

Figure 13. Global Pegfilgrastim Biosimilar Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Pegfilgrastim Biosimilar Sales Value Market Share by Type, 2023 & 2030

Figure 15. Global Pegfilgrastim Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Pegfilgrastim Biosimilar Sales Volume Market Share by Type, 2023 & 2030

Figure 17. Global Pegfilgrastim Biosimilar Price by Type (2019-2030) & (US$/Unit)

Figure 18. Product Picture of Hospital Pharmacies

Figure 19. Product Picture of Mail-Order Pharmacies

Figure 20. Product Picture of Retail Pharmacies

Figure 21. Global Pegfilgrastim Biosimilar Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 22. Global Pegfilgrastim Biosimilar Sales Value Market Share by Application, 2023 & 2030

Figure 23. Global Pegfilgrastim Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 24. Global Pegfilgrastim Biosimilar Sales Volume Market Share by Application, 2023 & 2030

Figure 25. Global Pegfilgrastim Biosimilar Price by Application (2019-2030) & (US$/Unit)

Figure 26. North America Pegfilgrastim Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 27. North America Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 28. Europe Pegfilgrastim Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 29. Europe Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 30. Asia Pacific Pegfilgrastim Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 32. South America Pegfilgrastim Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 33. South America Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 34. Middle East & Africa Pegfilgrastim Biosimilar Sales Value (2019-2030) & (US$ Million)

Figure 35. Middle East & Africa Pegfilgrastim Biosimilar Sales Value by Country (%), 2023 VS 2030

Figure 36. Key Countries/Regions Pegfilgrastim Biosimilar Sales Value (%), (2019-2030)

Figure 37. Key Countries/Regions Pegfilgrastim Biosimilar Sales Volume (%), (2019-2030)

Figure 38. United States Pegfilgrastim Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 39. United States Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 40. United States Pegfilgrastim Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 41. Europe Pegfilgrastim Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 42. Europe Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 43. Europe Pegfilgrastim Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 44. China Pegfilgrastim Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 45. China Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 46. China Pegfilgrastim Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 47. Japan Pegfilgrastim Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 48. Japan Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 49. Japan Pegfilgrastim Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 50. South Korea Pegfilgrastim Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 51. South Korea Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 52. South Korea Pegfilgrastim Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 53. Southeast Asia Pegfilgrastim Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 54. Southeast Asia Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 55. Southeast Asia Pegfilgrastim Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 56. India Pegfilgrastim Biosimilar Sales Value, (2019-2030) & (US$ Million)

Figure 57. India Pegfilgrastim Biosimilar Sales Value by Type (%), 2023 VS 2030

Figure 58. India Pegfilgrastim Biosimilar Sales Value by Application (%), 2023 VS 2030

Figure 59. Pegfilgrastim Biosimilar Industrial Chain

Figure 60. Pegfilgrastim Biosimilar Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Pegfilgrastim Biosimilar in 2030? zhanKai

The global market size of Pegfilgrastim Biosimilar in 2030 was 2407 Million USD.

Which region is expected to have the highest market share? shouQi

What is the annual compound growth rate of the global Pegfilgrastim Biosimilar market size from 2024 to 2030? shouQi

What was the global market size of Pegfilgrastim Biosimilar in 2024? shouQi

Which companies rank high in the global Pegfilgrastim Biosimilar market? shouQi

Related Reports

Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published Date: 2026-07-09
Pages: 135
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2026
The global Pegfilgrastim Biosimilar market was valued at US$ 1827 million in 2025 and is anticipated to reach US$ 2877 million by 2032, at a CAGR of 6.8% from 2026 to 2032.
Published Date: 2026-04-21
Pages: 108
USD 2900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-25
Pages: 149
USD 4900.00
(Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 106
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pegfilgrastim Biosimilar market size was US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 77
USD 4250.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published Date: 2025-02-21
Pages: 82
USD 2900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Insights, Forecast to 2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-04-25
Pages: 91
USD 4900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-02-07
Pages: 82
USD 2900.00
(Single User License)

Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published: 2026-07-09
Pages: 135
USD 3950.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2026
The global Pegfilgrastim Biosimilar market was valued at US$ 1827 million in 2025 and is anticipated to reach US$ 2877 million by 2032, at a CAGR of 6.8% from 2026 to 2032.
Published: 2026-04-21
Pages: 108
USD 2900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-25
Pages: 149
USD 4900.00 (Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 106
USD 3950.00 (Single User License)
Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pegfilgrastim Biosimilar market size was US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 77
USD 4250.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published: 2025-02-21
Pages: 82
USD 2900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Insights, Forecast to 2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-04-25
Pages: 91
USD 4900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-02-07
Pages: 82
USD 2900.00 (Single User License)